Alzheimer’s Drugs Race to FDA
On June 7, 2021, the FDA approved aducanumab (Aduhelm), an Alzheimer’s disease treatment targeting amyloid beta, using the accelerated approval pathway. As part of our review of 2021’s top stories, we look ahead at what the Alzheimer’s drug landscape looks like in the wake of the landmark FDA decision. No small part of the controversy surrounding …